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Summanr Carboplatin. a cisplatinum analogue, has no reported nephrotoxicity in phase I'II studies, assessed
by creatinine clearance. We prospectively deterniined renal function in 10 untreated lung cancer patients with
normal baseline renal function, treated with carboplatin 400mgm 2 day 1 and vincristine 2mg day 1 and 8
every 4 weeks (max. five cycles) by means of clearance studies with 1251-sodium thalamate and 1311-hippurate
to determine GFR and ERPF respectively. Tubular damage was monitored by excretion of tubular enzymes
and relative f2-microglobulin clearance. During the first course no changes in renal function were seen. After
the second course a significant fall in GFR and ERPF started, ultimately leading to a median decrease in
GFR of 19.0% (range 6.8-38.7%) and in ERPF of 14% (range 0-38.9%). No increases in the excretion of
tubular enzymes or changes in the relative fi-microglobulin clearances were seen. We conclude from our data
that carboplatin causes considerable loss of renal function. Monitoring renal function in patients treated with
multiple courses of carboplatin is warranted.
The introduction of cisplatin (CDDP) in the early seventies
resulted in a major step forward in anticancer chemotherapy
(Carter et al., 1984). However. cisplatin has a narrow
therapeutic index especially in regard to nephrotoxicity,
limiting the clinical utility of this agent (Madias &
Harrington. 1978). Several ways have been employed to
overcome this problem. Although therapeutic index of
CDDP has improved with the use of such manoeuvres, the
drug does remain nephrotoxic (Al-Sarraf et al., 1983; Ozols
et al.. 1984; Markham et al., 1985; Bodenner et al., 1986;
Elfenrnk et al., 1986; Offerman et al., 1985). An alternative
approach was the synthesis of analogues of cisplatin with the
aim to find Pt-complexes with less nephrotoxicity and more
or comparable antitumour activity (Burchenal et al., 1979).
About 2,000 second generation Pt-compounds have been
synthesised and screened for cytotoxicity. Only a few have
been selected for clinical evaluation, of which carboplatin
(CBDCA, JM8) probably is the most promising. In human
and animal studies carboplatin has demonstrated increased
haematological toxicity compared to CDDP, but it is less
emetogenic and has little or no oto- or neurotoxicity and no
nephrotoxicity even in the absence of forced diuresis
(Lelieveld et al.. 1984: Van Glabbeke et al., 1988). In these
studies the renal function was measured by monitoring
serum creatinine and creatinine clearances. However, the
determination of creatinine as a reflection of the glomerular
filtration rate has proved to be a relatively insensitive
method to monitor CDDP-induced renal damage (Meijer et
al., 1983; Daugaard et al., 1988). Moreover, using 52Cr
EDTA clearances, Calvert et al. (1982) were also unable to
identify CBDCA as a nephrotoxic drug.
In this study we prospectively determined changes in
glomerular filtration rate and effective renal plasma flow by
the more sensitive method developed by Donker et al. (1977)
in 10 patients treated with standard dose carboplatin. The
possible tubular damage was monitored by measuring the
excretion of tubular enzymes.
Methods
Patients and therapy
Ten patients, one female, nine male, were studied. All had
histologically proved lung cancer (eight small cell lung
cancer, one squamous cell carcinoma, one endobronchial
carcinoid). One patient was pretreated with s.c. infusion of
interferon, all others were previously untreated. Their age
ranged from 48 to 69 years (mean 58). All had a normal
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serum creatimne level < 120,umol 1 '. were normotensive,
not salt restricted, and did not use other potentially nephro-
toxic medication.
All patients were treated with carboplatin 400mgm 2 day
1 and vincristine 2mg day 1 and 8 every 4 weeks. Carbo-
platin was dissolved in 250ml of glucose 5% and given as a
30mn i.v. infusion on day 1. Vincristine was given as bolus
injection. No pre- or post-hydration was given.
Seven responding patients received the maximum of five
courses. The treatment had to be stopped in two patients
after three and in one patient after two courses. because of
tumour progression.
Renalfunction studies
Glomerular filtration rate (GFR) and effective renal plasma
flow (ERPF) were measured simultaneously in supine
position with radioisotopes. ERPF was determined by
measuring the clearance of 1311-hippuran (Ix V P) and GFR
by the clearance of '251-iothalamate (Ux V P) (I=counts per
minute of I ml sustaining solution, V=infusion volume or
urine volume in ml per minute, P=counts per minute in 2ml
of plasma and U=counts per minute in 2ml urine). After a
standard pnrmary dose and sustaining infusion for 2h, 1-h
clearances were determined for acute effects and 2-h clear-
ances for cumulative effects. For the latter. values are the
mean of two 2-h clearances, which were corrected for
standard body surface area. Errors in GFR introduced by
incomplete collection of urine were corrected to a method
previously described. The day to day variation of GFR is
2O2% and of ERPF <5% (Donker et al., 1977). Filtration
fraction (FF) was calculated as the quotient of GFR and
ERPF.
Creatinine clearances were also corrected for incomplete
collection of urine, using the same method as mentioned
above.
These vanrables were studied before and during four hours
after the first carboplatin infusion in order to determine
acute effects on renal function. Cumulative effects were also
measured during 4h 4 weeks after each course, just before
the administration of the following courses, i.e. on days 29,
57, 85. 113 and 141.
During renal function studies urine was collected hourly
for the determination of creatinine, LDH, alkaline phospha-
tase (ALP), gamma-GT and #2-microglobulin. Serum and
urine creatinine, urine LDH, ALP and gamma-GT were
determined with standard automatic techniques. f2-Micro-
globulin concentration in plasma and urine was determined
by a radioimmnunosorbent technique according to Evnrn et al.
(1971). Next the ratio of respectively LDH, ALP, gamma-
GT and creatinine (U per gram) were calculated. For fl2-
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microglobulin the relative clearance in respect to creatinine
clearance was calculated.
Statistics
Statistical analysis was performed with Wilcoxon's test for
paired observations (two-sided); P<0.05 was considered
indicative of a significant difference between groups.
Results
Acute effects
The pretreatment values (A) of ERPF, GFR and FF of all
patients are listed in Table I. Also depicted are the nadir
values of ERPF and values of GFR and FF corresponding
with the nadir values of ERPF after the first carboplatin
infusion (B). Also, corresponding creatinine clearances are
listed in Table I. There were no statistically significant
changes in the GFR, either by the radiochemical method or
creatinine clearances, and ERPF. For tubular enzymes no
changes were seen. Relative clearance of #2-microglobulin
increased in the 4h after carboplatin infusion, but remained
within the normal range.
Cumulative effects
Absolute and relative changes in GFR and ERPF during the
whole treatment are given in Table II and Figure 1, respec-
tively. Corresponding creatinine clearances are also given.
Four weeks after the first administration of carboplatin there
is still no significant change in ERPF, GFR and FF, but
deterioration of the renal function as measured by the
radioisotope clearances occurs after the second course. Out
of nine patients still on study 4 weeks after two courses,
seven had a fall in GFR >2% (P<0.02), median -7.5%,
range + 1.9% to -36.1%. In three patients ERPF decreased
>5% as opposed to pretreatment values; median -3.4%,
range +24.1% to -40.0% (P<0.05). The ultimate decrease
after five courses (n =7) ranges from 6.8% to 38.7% for
GFR (median 19.0%) (P<0.02) and for ERPF 1.6% to
38.9% (median 14%) (P<0.02). These changes could not be
explained by alteration in body weight of individual patients.
Although creatinine clearances showed a tendency to
decrease after course 2, this change was not significant
(P>0.1). Moreover, 4 weeks after the fourth course creati-
nine clearances retuned to baseline values, with the exception
of those in patient number 10. After five courses no
significant difference as opposed to pre-treatment values
were found.
During the observation period no significant changes in
serum creatinine were found. In regard to tubular enzymes
and relative f2 clearance we could not detect significant
changes. Also, none of the patients developed proteiniiria.
The most serious side effect of cisplatin is nephrotoxicity.
After multiple courses of CDDP, a decrease of about 40% in
creatinine clearance has been reported (Meijer et al., 1983;
Dentino et al., 1978). The study of Meijer et al. (1983), using
the same method as used in this report, showed a median
decrease in GFR and ERPF of both 23% after induction
chemotherapy containing CDDP for non-seminomatous tes-
ticular cancer. The cisplatin analogue carboplatin has no
reported nephrotoxicity at conventional dose levels. The
reduced protein binding (Van Echo et al., 1984; Gaver et al.,
1987) and greater stability of carboplatin in body fluids and
therefore increased renal excretion compared to cisplatin are
supposed to account for the absence of nephrotoxicity
(Harland et al., 1984; Sharma et al., 1983). Also, in animal
models, carboplatin enhanced nuclear protein phos-
phorylation in tumour cells more than CDDP did, but
caused much less protein phosphorylation in the normal liver
and kidney cells. This suggests some selective toxicity to-
wards tumour cells and may in part explain the decreased
nephrotoxicity of carboplatin (Harrap et al., 1980). There-
fore, carboplatin has been recommended as an alternative to
cisplatin in patients with impaired renal function or in those
who cannot receive the hydration required for conventional
cisplatin administration (Von Hoff, 1987).
There have been sporadic observations of renal function
deterioration after multiple courses of carboplatin (Calvert et
al., 1982; Van Glabbeke et al., 1988; Rozenczweig et al.,
1983; Leyvraz et al., 1985). Also, the high dose
(>800mgm-2) study of Gore et al. (1987) showed a fall in
GFR of >25% in 55% of courses, as measured by (5"Cr)
EDTA clearances.
Since vincristine has no reported nephrotoxicity (Schilsky,
1982; Weis & Poster, 1982), we conclude from the data of
our study that carboplatin has a cumulative dose related
nephrotoxic effect, as there was no decrease in renal function
parameters after the first course, but an impressive fall in
GFR and ERPF after the second course, ultimately leading
to a decrease of 38% after five courses in some patients. The
fall in GFR may be clinically important because the degree
of myelosuppression probably depends on GFR (Egorin et
al., 1984; Fish et al., 1987; Egorin et al., 1985). In our
patients, however, we did not find cumulative haemato-
logical toxicity despite this decrease in GFR. Even the
patient with a 38% reduction in GFR did not have severe
myelosuppression.
This study also shows the superiority of the radiochemical
Table I ERPF and GFR (creatinine clearance), all in mlmin-' 1.73m-2 before (A) and after (B) first
carboplatin infusion
Patient
3
4
5
6
7
8
9
10
Median
Mean
s.d.
s.e.m.
ERPF
A B
660
375
401
293
312
271
319
599
301
558
388
408.9
143.06
45.24
601
395
397
309
322
235
315
517
309
526
358.5
398
125.88
39.81
GFR (creatinine clearance)
121
118
155
87
83
80
105
123
102
143
A
(106)
(107)
(115)
(80)
(98)
(82)
(116)
(118)
(110)
(134)
111.5 (108.5)
111.7 (106.6)
25.14 (16.5)
7.95 (5.21)
119
136
158
92
94
81
102
130
113
154
B
(96)
(95)
(131)
(75)
(82)
(72)
(107)
(116)
(122)
(114)
121.5 (101.5)
117.9 (101)
26.39 (20.3)
8.34 (6.42)
FF
A B
0.18
0.30
0.39
0.28
0.27
0.30
0.33
0.21
0.34
0.26
0.29
0.286
0.0615
0.0194
0.20
0.35
0.39
0.30
0.29
0.34
0.32
0.23
0.37
0.29
0.31
0.308
0.0596
0.0188118 D.TH. SLEIJFER et al.
Table I Absolute changes in GFR (creatinine clarance) and ERPF, all in mlmin-I 1.73m-2 after multiple courses
Course nunber
Patient 0 1 2 3 4 5
GFR (creatinine clearance)
1 121 (106) 124 (112) 95 (79) 98 (93) 101 (105) 96 (129)
2 118 (107) 137 (124) 113 (101)
3 155 (115) 116 (100) 99 (116) 97 (109) 94 (179) 95 (68)
4 87 (80) 97 (125) 82 (93) 91 (97) 87 (111) 81 (59)
5 83 (98) 90 (114) 78 (101)
6 80 (82) 79 (85) 74 (87) 73 (84) 72 (81) 62 (91)
7 105 (116) 102 (113) 107 (72) 101 (109) 89 (107) 85 (91)
8 123 (118) 131 (102) 124 (143) 120 (145) 119 (123) 114 (127)
9 102 (110) 116 (120)
10 143 (134) 111 (90) 110 (90) 98 (79) 103 (50) 122 (116)
Median 111.5 (110) 116 (112.5) 99 (93) 98 (97) 94 (111) 95 (91)
Mean 111.7 (106.5) 110.3 (108.5) 98 (99) 96.9 (102.3) 95.0 (108) 93.6 (97)
s.d. 25.14 (16.5) 18.35 (13.8) 17.20 (22.5) 13.90 (22.0) 14.75 (39.5) 10.26 (27.8)
s.e.m. 7.95 (5.21) 5.80 (4.37) 5.73 (7.49) 5.25 (8.31) 5.58 (14.94) 7.66 (10.5)
ERPF
1 660 540 396 413 423 403
2 375 492 424
3 401 470 407 360 320 310
4 293 331 283 350 288 290
5 312 376 302
6 271 260 260 254 249 234
7 319 354 3% 372 330 314
8 599 554 499 531 558 555
9 301 452
10 558 385 374 348 382 398
Median 388 418.5 396 360 330 314
Mean 408.9 421.4 371.2 375.4 364.3 357.7
s.d. 143.06 95.50 76.30 83.67 102.90 105.41
s.e.m. 45.24 30.20 25.43 31.63 38.89 39.84
20
10
0
-10
-20
20
10
0
-10
-20
a
b
Fgwe 1 Mean percent changes in GFR (mlmin-' 1.73m-2)
(a) and ERPF (mlmin - 1.73 m-2) (b) after multiple courses
of carboplatin (mean +s.e.).
method to determine GFR as opposed to creatinine clear-
ance in order to monitor Pt induced renal damage. The
latter method failed to detect a significant change in GFR
after multiple courses of carboplatin. A possible explanation
for this finding is provided by Meyer et al. (1983). A
significant fall in GFR (median 23%) was seen after com-
bination chemotherapy containing CDDP, without a rise in
serum creatinine. They suggested that the chemotherapy
interfered with enzymic systems required for creatinine
production.
The mode of action of Pt-induced nephrotoxicity remains
unknown. Offerman et al. (1984) have shown that the acute
effect of CDDP on renal function is a fall in ERPF
preceding a similar change in GFR. Also, in experimental
models of renal failure following intoxication with heavy
metals, in the initial phase a reduction of renal blood flow
can be found. In our study no such phenomenon could be
found, as during the first course neither a fall in GFR nor in
ERPF was seen. Since a simultaneous decrease in both GFR
and ERPF occurred 4 weeks after course 2, we can only
speculate, but not exclude, whether such a sequence of
events did take place. Also, the intracellular presence of
reactive Pt-compounds in the kidney is suggested to relate to
this toxicity (Harland et al., 1984; Stewart et al., 1985).
Therefore tubular damage might play an important role in
Pt-induced nephrotoxicity. The reported renal uptake of
carboplatin does not differ substantially from that for
CDDP (Lelieveld et al., 1984; Owens et al., 1985). CDDP
induces tubular damage in most patients but we could not
find signs of tubular damage after carboplatin adminis-
tration as measured by the urinary excretion of tubular
enzymes, because of infrequent sampling. For the evaluation
of tubular damage timing of specimen collection plays an
important role (Goren et al., 1987). As reported for cisplatin
(Goren et al., 1986) and carboplatin (Egorin et al., 1984),
urinary enzymes can peak as late as several days after the
administration of the drug. Shillen et al. (1988) collected
weekly specimens for the evaluation of excretion of urinaryCARBOPLATIN AND RENAL FUNCTION 119
protein and enzymes in patients receiving multiple courses of
carboplatin 400mgm .2 In some of their patients urinary
enzymes peaked 2 weeks after the administration of the
drug. Therefore, our results might be misleading in tha they
were obtained for a period of only 4h after administration.
We conclude from our data that carboplatin exerts dose-
related cumulative renal damage. Careful monitoring,
especially with regard to myelosuppression, in patients with
impaired renal function or those pretreated with Pt contain-
ing regimens is therefore warranted. The observed reduction
in renal function after carboplatin is in the same range
compared to patients treated with cisplatin with saline
diuresis (Meijer et al., 1983). Although it has not been
excluded that hyperhydration during carboplatin treatment
could prevent the nephrotoxic effects, the value of adminis-
tering this cytostatic drug on an outpatient base would
disappear.
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